DJIA 16,960.57 -123.23 -0.72%
NASDAQ 4,449.56 -22.54 -0.50%
S&P 500 1,978.34 -9.64 -0.48%
market minute promo

Verastem, Inc. (NASDAQ: VSTM)

8.30 -0.10 (-1.19%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

VSTM $8.30 -1.19%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $8.27
Previous Close $8.40
Daily Range $8.13 - $8.40
52-Week Range $7.10 - $16.60
Market Cap $214.4M
P/E Ratio -4.44
Dividend (Yield) $0.00 (0.0%)
Volume 135,926
Average Daily Volume 231,881
Current FY EPS -$2.10

Sector

Healthcare

Industry

Drugs

Verastem, Inc. (VSTM) Description

Verastem Inc is a biopharmaceutical company focused on discovering and developing proprietary small molecule drugs targeting cancer stem cells along with proprietary companion diagnostics. Website: http://www.verastem.com/

News & Commentary Rss Feed

Today's Biggest Biotech Stories: BioCryst, Verastem, and InterMune

BioCryst, Verastem, and InterMune could all loom large in health care headlines this morning. Here's why.

Verastem (VSTM) Crumbles: Stock Falls by 6.1% - Tale of the Tape

Verastem (VSTM) in Focus: Stock Adds 14% in Session - Tale of the Tape

Healthcare Stocks Mixed; Verastem Surges After Publishing Supportive Data for Its Anti-Cancer Therap

Healthcare Stocks Mixed; Verastem Surges After Publishing Supportive Data for Its Anti-Cancer Therapy

Sector Update: Healthcare

UPDATE: Deutsche Bank Initiates Coverage On Verastem On Multiple Positive Factors

Oversold Conditions For Verastem (VSTM)

Verastem: Cancer May Have Met Its Match

Verastem Becomes Oversold (VSTM)

Verastem's CEO Discusses Q4 2013 Results - Earnings Call Transcript

Verastem Reports Data from Phase 1 Study of VS-6063 (defactinib) in Japanese Patients; Completes Ful

Verastem Reports Data from Phase 1 Study of VS-6063 (defactinib) in Japanese Patients; Completes Full Enrollment and was "Well Tolerated" at Each Dosage Level

See More VSTM News...